Executive Summary
Best-in-class ALK inhibitor with TRK-sparing selectivity designed to overcome lorlatinib resistance
Key Differentiators
- 60% of patients progress on 2L lorlatinib within 24 months
- Compound mutations emerge after lorlatinib with limited treatment options
- TRK-related toxicity with current ALK TKIs
neladalkib
ALK · kinase inhibitor
Target: ALK
Full NameAnaplastic Lymphoma Kinase
PathwayALK fusion (EML4-ALK) → constitutive kinase activation → tumor growth
Mechanism of Action
Indications: ALK+ NSCLC (TKI pre-treated)ALK+ NSCLC (TKI-naïve)ALK+ solid tumors (non-NSCLC)
Target Biology
ALK is a receptor tyrosine kinase that when fused to partner genes like EML4 creates oncogenic fusion proteins driving tumor growth. ALK fusions occur in 3-5% of NSCLC, typically in younger patients with significant impact on quality of life.
Clinical Data
ALKOVE-1 (NCT05384626)
Phase 1/2Design: Global open-label multi-cohort study
Study Populations
| Cohort | N | Description |
|---|---|---|
| Tki Pretreated Pivotal | 253 | ALK+ NSCLC with ≥1 prior ALK TKI, data cutoff Aug 29, 2025 |
| Lorlatinib Naive | 63 | Subset without prior lorlatinib |
| Lorlatinib Experienced | 190 | Subset with prior lorlatinib |
| Tki Naive Exploratory | 44 | TKI-naïve patients (exploratory) |
| Alk Solid Tumors | 34 | Non-NSCLC ALK+ solid tumors |
Safety
- Discontinuation Rate: 5%
- Dose Reduction Rate: 17%
- Alt Elevation: 47% any grade (20% Gr3+)
- Ast Elevation: 44% any grade (16% Gr3+)
- Transaminase Note: Asymptomatic and reversible
- Key Differentiator: TRK-sparing design (>20x selectivity ALK vs TRKB)
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Key Risks
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Lorlatinib's dominant 1L position (mPFS not reached at 60 mo) | — | |
| ALKAZAR Phase 3 execution and enrollment | — | |
| Transaminase elevations may limit some patients | — |
Peak Sales Estimate:
$1.35B-$2.0B US with frontline expansion
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| NDA submission | 1H 2026 | critical | FDA acceptance and review timeline | — |
| ALKAZAR Phase 3 enrollment completion | 2026 | high | Enrollment pace for 1L head-to-head vs alectinib | — |